On the propriety of collaborations between academicians and the pharmaceutical industry: An alternate viewpoint

World Psychiatry

Volumn 6, Issue 1, 2007, Pages 29-31

  Thase, Michael E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

COMMERCIAL PHENOMENA; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS; FINANCE; NOTE; PATENT; PRIORITY JOURNAL; PSYCHIATRY; UNIVERSITY;

EID: 34250192149     PISSN: 17238617     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Thase ME. The next step forward: a move toward evidence, and away from fear of the industry. Psychopharmacol Bull 2002; 36:4-5.
2. Healy D, Thase ME. Is academic psychiatry for sale? Br J Psychiatry 2003;182:388-90.
3. Freemantle N, Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. Br J Psychiatry 2000;177:292-302.
4. Perlis RH, Perlis CS, Wu Y et al. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 2005;162: 1957-60.
5. Gaffan EA, Tsaousis I, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. J Consult Clin Psychol 1995; 63:966-80.